Vaccines & Emerging Diseases | Conference Series | International Scientific and Medical Conferences

Theme: Vaccine Development and Delivery Innovations

GLOBAL VACCINE 2025

GLOBAL VACCINE 2025

Welcome to the 2^nd Global Summit on Vaccines and Emerging Diseases Conference 2025, taking place on April 28-29, 2025 in the picturesque and culturally rich island of Bali, Indonesia with the theme of “Vaccine Development and Delivery Innovations”. We are delighted to host this important event, bringing together a diverse group of experts, researchers, healthcare professionals, and policymakers from around the world.

This conference aims to foster dialogue and collaboration on the latest advancements in vaccine development and the ongoing challenges posed by emerging infectious diseases. Over the next two days, we will explore a wide range of topics, including innovative vaccine technologies, global health strategies, and cutting-edge research in immunology. Our distinguished line-up of keynote speakers, interactive panel discussions, and specialized workshops are designed to provide you with valuable insights and practical knowledge. This is an excellent opportunity to network with peers, share your own expertise, and establish collaborations that can drive forward the field of vaccinology and public health.

Who to attend:

The Vaccines & Emerging Diseases Conference 2025 is designed for a diverse audience, bringing together professionals from various fields who are dedicated to advancing the science of vaccines and improving responses to emerging infectious diseases. Attendees will benefit from the opportunity to engage with cutting-edge research, share knowledge, and form valuable collaborations. The following groups of professionals are particularly encouraged to attend:

Directors, CEO’s of Organizations
Researchers and Scientists
Healthcare Professionals
Industry Professionals
Policy Makers and Government Officials
Non-Governmental Organizations (NGOs) and International Organizations
Academics and Educators
Students and Early Career Professionals
Investors and Financial Analysts
Media and Communication Professionals
Technology and Innovation Experts

This conference is an essential event for anyone involved in the fields of vaccinology and infectious disease control, offering a comprehensive overview of current research, challenges, and opportunities in these critical areas.

Session 01: Vaccines and Emerging Diseases

Vaccines play a crucial role in combating emerging diseases, which are often characterized by new or rapidly evolving pathogens that pose significant public health threats. As new infectious agents emerge or re-emerge, vaccines are developed to provide protection and control their spread. The process involves identifying the pathogen, understanding its characteristics, and designing vaccines that elicit a strong and targeted immune response.

Session 02: Innovative Vaccine Development

Innovative vaccine development is at the forefront of modern medicine, leveraging cutting-edge technologies to create more effective and safer vaccines. Recent advancements include the development of mRNA vaccines, which have revolutionized the speed and flexibility of vaccine production, as demonstrated during the COVID-19 pandemic.

Session 03: Pandemic Preparedness and Response

Pandemic preparedness and response are essential components of global health security, aimed at preventing and mitigating the impact of widespread infectious disease outbreaks. Effective preparedness involves developing and maintaining robust surveillance systems to detect early signs of emerging threats, ensuring rapid and accurate diagnostic capabilities, and creating scalable healthcare infrastructure.

Session 04: Technological Innovations in Vaccinology

Technological innovations in vaccinology are revolutionizing the development and effectiveness of vaccines, driven by advancements in various scientific disciplines. Cutting-edge technologies such as mRNA and viral vector platforms have accelerated vaccine production and enhanced immune responses with precision and flexibility. Innovations in nanotechnology are improving vaccine delivery and targeting, while artificial intelligence and machine learning are streamlining vaccine design and predicting potential vaccine candidates.

Session 05: Clinical Trials and Regulatory Affairs

Clinical trials and regulatory affairs are critical components in the development and approval of vaccines, ensuring that they are both safe and effective for public use. Clinical trials follow a rigorous, multi-phase process to evaluate a vaccine's efficacy, safety, and optimal dosage, involving diverse participant groups to assess its impact across different populations. Each phase of the trial provides valuable data, from initial safety assessments in small groups to broader efficacy studies in larger populations.

Session 06: Vaccine Access and Equity

Vaccine access and equity are fundamental to achieving global health goals, ensuring that all populations, regardless of geographic, economic, or social barriers, receive timely and adequate protection against preventable diseases. Addressing disparities involves overcoming logistical challenges in vaccine distribution, such as supply chain issues and cold storage requirements, and ensuring affordable pricing through equitable pricing strategies and international collaboration.

Session 07: Cancer Vaccines and Immunotherapy

Cancer vaccines and immunotherapy are pioneering strategies in oncology, utilizing the immune system to target and destroy cancer cells. Cancer vaccines aim to activate the immune system to identify and combat specific cancer-related antigens, with options for both therapeutic vaccines to treat active cancer and preventive vaccines to lower the risk of developing certain cancers. Immunotherapy encompasses a variety of methods, including checkpoint inhibitors that disrupt proteins inhibiting immune activity, and CAR-T cell therapy, which involves engineering a patient’s T cells to more effectively recognize and attack cancer cells. These advanced treatments represent a significant shift towards more personalized and targeted approaches in cancer care.

Session 08: Vaccine Research and Development

Vaccine research and development is a multifaceted process focused on creating and refining vaccines to prevent and control infectious diseases. It begins with basic research to identify potential antigens and understand pathogen mechanisms, followed by preclinical studies to assess vaccine candidates in laboratory models. Successful candidates advance to clinical trials, where they undergo rigorous testing in human subjects to evaluate safety, efficacy, and optimal dosing. The development phase also involves addressing regulatory requirements, ensuring compliance with health standards, and preparing for large-scale manufacturing and distribution.

Session 09: Emerging Technologies in Diagnostics

Emerging technologies in diagnostics and therapeutics are revolutionizing the way diseases are detected and treated, offering new possibilities for precision medicine. In diagnostics, advancements include next-generation sequencing, which allows for rapid and comprehensive genetic analysis, and innovative imaging techniques that provide detailed insights into disease progression and treatment response. Additionally, artificial intelligence and machine learning are being used to analyze complex data sets, improving diagnostic accuracy and enabling early disease detection. In therapeutics, new drug delivery systems, such as nanoparticle-based carriers and targeted therapies, are enhancing the precision and effectiveness of treatments.

Session 10: Nanotechnology in vaccines

Nanotechnology is transforming vaccine development by enabling the creation of more effective and targeted vaccines. By using nanoparticles as carriers, researchers can enhance the stability and delivery of vaccine antigens, leading to improved immune responses. Nanoparticles can be engineered to mimic pathogen structures, which helps to elicit a stronger immune reaction. Additionally, nanotechnology allows for the development of controlled-release systems that can gradually release antigens, potentially reducing the need for multiple doses.

Session 11: Epidemiology and Public Health

Epidemiology and public health are crucial fields that focus on understanding and improving population health through the study of disease patterns, causes, and effects. Epidemiology involves the analysis of data to identify risk factors and determine the distribution of diseases within populations. This includes tracking disease outbreaks, assessing the impact of environmental and genetic factors, and evaluating the effectiveness of public health interventions.

Session 12: Immunization Programs and Strategies

Immunization programs and strategies are vital components of public health initiatives aimed at preventing infectious diseases and protecting community health. These programs involve the systematic administration of vaccines to individuals or populations, with the goal of achieving high vaccination coverage to establish herd immunity and control disease outbreaks.

Session 13: Biosecurity and Bioterrorism Preparedness

One Health approaches to viral diseases emphasize the interconnectedness of human, animal, and environmental health in preventing and managing outbreaks. This integrated strategy recognizes that many viral diseases are zoonotic, originating in animals and spreading to humans, and that disruptions in ecosystems can influence disease dynamics. By promoting collaboration among veterinarians, medical professionals, environmental scientists, and public health experts, One Health approaches aim to enhance surveillance and early detection of viral threats.

Session 14: Next-Generation Vaccine Delivery Technologies

Next-generation vaccine delivery technologies are advancing the way vaccines are administered, aiming to enhance efficacy, convenience, and patient compliance. Innovations include needle-free delivery systems such as microneedle patches and jet injectors, which offer a less invasive and more comfortable vaccination experience. Additionally, technologies like nanoparticle-based carriers are being developed to improve antigen stability and targeted delivery, potentially reducing the need for multiple doses.

Session 15: Vaccine Adjuvants

Vaccine adjuvants are crucial components that enhance the immune response to vaccines, improving their effectiveness and duration of protection. These substances work by stimulating the immune system and boosting the body's response to the vaccine's antigens. Adjuvants can function through various mechanisms, such as increasing antigen uptake by immune cells, promoting the activation of immune pathways, or extending the time the antigen remains in the body.

Session 16: Veterinary vaccines

Veterinary vaccines are essential tools in managing and preventing diseases in animals, ranging from livestock to companion animals. These vaccines are designed to protect against a variety of infectious diseases, including bacterial, viral, and parasitic infections, thereby improving animal health, productivity, and welfare. Veterinary vaccines work by stimulating the animal's immune system to recognize and combat specific pathogens, reducing the incidence and severity of diseases.

Session 17: HIV Vaccines

HIV vaccines are a critical area of research aimed at preventing and ultimately eradicating HIV infection. These vaccines are designed to stimulate the immune system to recognize and combat the HIV virus, either by inducing a protective immune response before infection or by enhancing the body’s ability to control the virus in those already infected. Despite significant progress, developing an effective HIV vaccine remains challenging due to the virus’s ability to rapidly mutate and evade the immune system. Current research focuses on various strategies, including the use of broadly neutralizing antibodies, viral vector-based vaccines, and innovative adjuvants to enhance immune responses.

Session 18: Conjugate Vaccine

Conjugate vaccines represent a sophisticated approach to immunization, particularly effective against bacterial infections that are difficult to address with traditional vaccines. These vaccines work by linking a polysaccharide antigen from a bacterial capsule to a protein carrier, which enhances the immune system's ability to recognize and respond to the pathogen. This conjugation not only improves the vaccine's efficacy but also extends its protective effects to infants and young children, whose immune systems may not respond adequately to polysaccharide antigens alone.

Session 19: Thermo-stabilized vaccines

Thermo-stabilized vaccines are designed to maintain their efficacy and safety without the need for stringent cold storage, addressing a major challenge in vaccine distribution, especially in resource-limited settings. These vaccines incorporate advanced stabilization technologies that protect the vaccine components from degradation caused by temperature fluctuations. Techniques such as lyophilisation (freeze-drying), the use of stabilizing agents, and novel formulations are employed to ensure that vaccines remain effective even at higher temperatures.

To foster discussions, share expertise and exchange knowledge and best practices at all levels of the healthcare spectrum.
To encourage collaboration and enhance interactions at a global level.
Meet a range of specialists actively practicing in the field.
Strengthen your profile and position your organization as a key industry figure.
Develop new partnerships and networks with key decision-makers/influencers.
Open doors for your organization to connect and develop strategic relationships in a neutral and relaxed sales environment.
Get access to the targeted audience.
Brand Exposure – Promote your company’s message, products, and services through a national Conference marketing campaign.
First-hand live demonstrations to delegates.
To showcase new healthcare technologies and solutions in an intimate setting focused specifically on Vaccine & Emerging Diseases.
Your Speaker & Abstract pages on Google under your name will receive worldwide visibility, enhancing your professional profile.
Our robust online publicity attracts over 30,000 users and 50,000 views to our Library of Abstracts, providing researchers and speakers with global exposure.
Connect and exchange ideas with hundreds of industry leaders in Vaccines & Emerging Diseases, fostering valuable collaborations and partnerships.
Participate in one-to-one meetings with renowned keynote speakers and eminent researchers, gaining insights and expertise.
Attend keynote sessions led by world-renowned researchers, providing unique insights into the latest advancements in Vaccines & Emerging Diseases.
Gain access to strategic knowledge and expertise through our intensive conference schedule, enhancing your skills and capabilities.

The global market on GLOBAL VACCINE 2025, valued at USD 76.08 billion in 2023, is projected to grow at a CAGR of 5.74% from 2024 to 2030. This growth is driven by an increasing focus on vaccines targeting diseases in lower-income countries. In the U.S., the COVID-19 vaccine market has shifted to a commercial phase following the depletion of government-purchased stock, likely leading to higher prices, as seen with Moderna's March 2023 announcement that its COVID-19 vaccine would cost between USD 110 and USD 130 per dose. This market privatization is expected to heighten competition among manufacturers in the post-pandemic landscape.

In March 2023, the Serum Institute of India announced its expansion plans beyond COVID-19 vaccines by developing new vaccines for malaria and dengue. The company has repurposed its COVID-19 vaccine manufacturing facilities to produce these new vaccines, potentially increasing its annual production capacity to 4 billion doses. This strategic decision enables the Serum Institute to maintain high production levels and ensure a rapid response capability for future pandemics.

The COVID-19 pandemic has exposed the limitations of relying solely on public investment and procurement strategies for optimal public health outcomes. Despite the global distribution of approximately 15 billion vaccine doses by October 2022, only 12% were provided through COVAX, underscoring the need for more comprehensive approaches to ensure equitable distribution and prepare for future pandemics.

Regulatory agencies and networks, with support from the World Health Organization (WHO), have played a crucial role in improving vaccine accessibility by enhancing regulatory capacity and promoting coordinated efforts across countries. As a result, national regulatory authorities in 35 vaccine-producing countries have achieved the necessary maturity to oversee vaccine development, manufacturing, and distribution.

Planning a trip to Bali, Indonesia? Attend our Meeting!

Issue with VISA?

To support participants in their VISA application process, we provide VISA support documents as follows:

Official Letter of Invitation
Official Letter of Abstract Acceptance
Receipt of Payment

Points to note:

Visa Letter (official letter of invitation) will be issued only after successful registration and payment for the conference.

Visa Letters can be issued only for the individual accepted to attend the conference. Please contact the Program Manager, Andrea, via medicine@meetingsseries.com to arrange for a Visa Letter.

Kindly provide us with the following information for Visa Letters:

Your name as it appears on your passport
Passport Scan Copy (for passport number and date of birth)
Abstract Acceptance letter for Presenters

Payment Methods:

Payment Gateway/RAZORPAY
Bank-to-Bank transfer

Having trouble with registration?

Please contact Program Manager Alina Walsh, via medicine@meetingsseries.com. The GLOBAL VACCINE 2025 team will provide you with an INVOICE for the requested price, enabling you to make the Bank-to-Bank transfer.

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	April 28-29, 2025
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Abstracts will be provided with Digital Object Identifier by

2^nd Global Summit on Vaccines & Emerging Diseases April 28-29, 2025 Bali, Indonesia

Recommended Global Vaccines Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

GLOBAL VACCINE 2025

Conference Highlights

To Collaborate Scientific Professionals around the World

Useful Links

Special Issues